Cardiometabolic Consequences And Pathway Of Weight Gain Associated With Dolutegravir-Based Antiretroviral Therapy In Haiti. A Collaborative Study Between GHESKIO And CCASAnet
The following grant was awarded by, is supported by, is administered by or is in partnership with the Fogarty International Center at the U.S. National Institutes of Health (NIH).
Funding Fogarty Program
HIV-associated Noncommunicable Diseases Research at LMIC Institutions
Project Information in NIH RePORTER
Cardiometabolic Consequences And Pathway Of Weight Gain Associated With Dolutegravir-Based Antiretroviral Therapy In Haiti. A Collaborative Study Between GHESKIO And CCASAnet
Principal Institution
GHESKIO Center
Principal Investigator(s) (PI)
Pierre, Samuel; Koethe, John
Project Contact Information
Email:
spierre@gheskio.org
Year(s) Awarded
2023-2025
Country
Haiti
Project Description
People living with HIV (PLWH) have a higher risk of developing metabolic and cardiovascular diseases, which are leading causes of mortality among residents of low- and middle-income countries (LMICs). Weight gain is common after starting integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy, which is increasingly being used for HIV treatment in LMICs. This study will assess the prevalence of cardiometabolic disease among PLWH who gain weight on INSTI-based regimens in LMICs, and the metabolic and lipid pathways contributing to weight gain.
Related World Regions / Countries
Related Global Health Research Topics